MedPath

Prospective Observational Study of Efficacy and Safety in Chemotherapy After Refractory or Intolerant to Nivolumab Therapy for Unresectable Advanced or Recurrent Gastric Cancer

Not Applicable
Conditions
Advanced or recurrent gastric cancer
Registration Number
JPRN-UMIN000032182
Lead Sponsor
Public Health Research Foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients for whom the attending physician considered enrollment in the study inappropriate

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath